Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
ELISA developed for amino-terminally truncated beta-amyloid peptide quantitation
August 26th, 2005
An ELISA was developed to quantitate amino-terminally truncated beta-amyloid peptides. According to a study from Belgium, "Clinical studies for disease modifying drugs in Alzheimer's disease are in real need for a sensitive biochemical diagnostic and therapeutic marker. "Encouraging results have been obtained by measuring levels of pathology related proteins such as amyloid beta (A beta) peptides and tau proteins in cerebrospinal fluid (CSF) and plasma of patients." "We and other research groups have shown that truncated A beta 11-40 and A beta 11-42 is also a potential marker and that it is produced and deposited in the brains of...
Source: Drug Week (2005-08-26)
|
